Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00146029 · ClinicalTrials.gov registry record
Companion Pharmacogenetic Study to UMCC 9900/9901
A clinical trial, sponsored by University of Michigan Rogel Cancer Center.
- Terminated
- Registry status
NCT00146029: Clinical Trial study, sponsored by University of Michigan Rogel Cancer Center.
NCT00146029 is a clinical trial that was terminated before completion, run by University of Michigan Rogel Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00146029 was terminated before completion, sponsored by University of Michigan Rogel Cancer Center.
- TERMINATED
- Registry status
Study Summary
The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if this is in any way associated with how the patient responded to docetaxel. They also want to examine the genes in the tumor that are responsible for the production of CYP metabolizing enzymes, to see if they are normal or if they have polymorphisms, or change compared to 'normal' CYP metabolizing enzymes.
Trial Details
| Field | Value |
|---|
Why NCT00146029 stopped before completion
NCT00146029 is an observational study that tracks outcomes without assigning an intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 0 interventions.
NCT00146029 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00146029 about?
NCT00146029 is a clinical study titled "Companion Pharmacogenetic Study to UMCC 9900/9901". The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if this is in any way associated with how the patient responded to docetaxel. They also want to examine the genes in the tumor that...
What is the current status of trial NCT00146029?
This trial is currently terminated.
Who is sponsoring clinical trial NCT00146029?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.